Assess whether a safety signal is noise, confounding, or a real risk (9ab188)

Situation

A safety signal is sits with pediatric-plan strategist because a site-change that invalidates stability claims hit a 505(b)(2) program relying on literature plus a bridging study. Evidence is advisory-committee question list that exposes a weak secondary endpoint; write the Pharma & Life Sciences Clinical and Evidence Strategy option that extract can carry.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose A safety signal is noise, confounding, / A real risk using advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims.

Hypotheses to test

• The population in advisory-committee question list that exposes a weak secondary endpoint is the one a site-change that invalidates stability claims named, so A safety signal is noise, confounding, follows for this Clinical and Evidence Strategy file.
• The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a site-change that invalidates stability claims; A real risk is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a site-change that invalidates stability claims before advisory-committee question list that exposes a weak secondary endpoint arrived; no new Clinical and Evidence Strategy path.
• Provenance on advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims is broken; do not pick A safety signal is noise, confounding, or A real risk yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a safety signal is.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a site-change that invalidates stability claims and write the one fact that would move a safety signal is for pediatric-plan strategist.

Recommendation